Literature DB >> 25042049

Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model.

Jennifer A Flemming1, Ju Dong Yang, Eric Vittinghoff, W Ray Kim, Norah A Terrault.   

Abstract

BACKGROUND: All patients with cirrhosis are at risk of developing hepatocellular carcinoma (HCC). This risk is not uniform because other patient-related factors influence the risk of HCC. The objective of the current study was to develop an HCC risk prediction model to estimate the 1-year probability of HCC to assist with patient counseling.
METHODS: Between 2002 and 2011, a cohort of 34,932 patients with cirrhosis was identified from a national liver transplantation waitlist database from the United States. Cox proportional hazards regression methods were used to develop and validate a risk prediction model for incident HCC. In the validation cohort, discrimination and calibration of the model was examined. External validation was conducted using patients with cirrhosis who were enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) study.
RESULTS: HCC developed in 1960 patients (5.6%) during a median follow-up of 1.3 years (interquartile range, 0.47 years-2.83 years). Six baseline clinical variables, including age, diabetes, race, etiology of cirrhosis, sex, and severity (ADRESS) of liver dysfunction were independently associated with HCC and were used to develop the ADRESS-HCC risk model. C-indices in the derivation and internal validation cohorts were 0.704 and 0.691, respectively. In the validation cohort, the predicted cumulative incidence of HCC by the ADRESS-HCC model closely matched the observed data. In patients with cirrhosis in the HALT-C cohort, the model stratified patients correctly according to the risk of developing HCC within 5 years.
CONCLUSIONS: The ADRESS-HCC risk model is a useful tool for predicting the 1-year risk of HCC among patients with cirrhosis.
© 2014 American Cancer Society.

Entities:  

Keywords:  Scientific Registry of Transplant Recipients (SRTR); cirrhosis; hepatocellular carcinoma; liver cancer; risk factors; risk model

Mesh:

Year:  2014        PMID: 25042049      PMCID: PMC4553222          DOI: 10.1002/cncr.28832

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II.

Authors:  Takehiro Michikawa; Manami Inoue; Norie Sawada; Motoki Iwasaki; Yasuhito Tanaka; Taichi Shimazu; Shizuka Sasazuki; Taiki Yamaji; Masashi Mizokami; Shoichiro Tsugane
Journal:  Prev Med       Date:  2012-06-04       Impact factor: 4.018

2.  Analytical methods and database design: implications for transplant researchers, 2005.

Authors:  G N Levine; K P McCullough; A M Rodgers; D M Dickinson; V B Ashby; D E Schaubel
Journal:  Am J Transplant       Date:  2006       Impact factor: 8.086

3.  Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.

Authors:  Man-Fung Yuen; Yasuhito Tanaka; Daniel Yee-Tak Fong; James Fung; Danny Ka-Ho Wong; John Chi-Hang Yuen; David Yiu-Kuen But; Annie On-On Chan; Benjamin Chun-Yu Wong; Masashi Mizokami; Ching-Lung Lai
Journal:  J Hepatol       Date:  2008-09-21       Impact factor: 25.083

Review 4.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

Review 5.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.

Authors:  A Poonawala; S P Nair; P J Thuluvath
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

7.  Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.

Authors:  Jessica A Davila; Louise Henderson; Jennifer R Kramer; Fasiha Kanwal; Peter A Richardson; Zhigang Duan; Hashem B El-Serag
Journal:  Ann Intern Med       Date:  2011-01-18       Impact factor: 25.391

8.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

9.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.

Authors:  Anna S Lok; Leonard B Seeff; Timothy R Morgan; Adrian M di Bisceglie; Richard K Sterling; Teresa M Curto; Gregory T Everson; Karen L Lindsay; William M Lee; Herbert L Bonkovsky; Jules L Dienstag; Marc G Ghany; Chihiro Morishima; Zachary D Goodman
Journal:  Gastroenterology       Date:  2008-09-18       Impact factor: 22.682

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  54 in total

1.  Percutaneous radiofrequency ablation of hepatocellular carcinoma in cirrhosis: analysis of complications in a single centre over 20 years.

Authors:  Antonio Giorgio; Maria G Merola; Luca Montesarchio; Francesca Merola; Pietro Gatti; Carmine Coppola; Valentina Giorgio; Giorgio Calisti
Journal:  Br J Radiol       Date:  2017-05-25       Impact factor: 3.039

Review 2.  Surveillance of the Patients with High Risk of Hepatocellular Cancer.

Authors:  Necati Örmeci
Journal:  J Gastrointest Cancer       Date:  2017-09

3.  Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.

Authors:  George N Ioannou; Pamela K Green; Lauren A Beste; Elijah J Mun; Kathleen F Kerr; Kristin Berry
Journal:  J Hepatol       Date:  2018-08-21       Impact factor: 25.083

Review 4.  Liver cancer screening in high-risk populations.

Authors:  Morris Sherman
Journal:  Hepat Oncol       Date:  2015-11-30

Review 5.  Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis.

Authors:  Jens U Marquardt; Marc Nguyen-Tat; Peter R Galle; Marcus A Wörns
Journal:  Visc Med       Date:  2016-04-08

6.  Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program.

Authors:  Monica A Konerman; Aashesh Verma; Betty Zhao; Amit G Singal; Anna S Lok; Neehar D Parikh
Journal:  Liver Transpl       Date:  2019-03       Impact factor: 5.799

7.  Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA.

Authors:  Neehar D Parikh; Sherry Fu; Huiying Rao; Ming Yang; Yumeng Li; Corey Powell; Elizabeth Wu; Andy Lin; Baocai Xing; Lai Wei; Anna S F Lok
Journal:  Dig Dis Sci       Date:  2017-09-25       Impact factor: 3.199

8.  Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.

Authors:  Ju Dong Yang; Hager Amed Mohamed; Jessica L Cvinar; Gregory J Gores; Lewis R Roberts; W Ray Kim
Journal:  Am J Gastroenterol       Date:  2016-08-16       Impact factor: 10.864

Review 9.  Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.

Authors:  Lisa X Deng; Neil Mehta
Journal:  Dig Dis Sci       Date:  2020-12       Impact factor: 3.199

10.  Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging?

Authors:  Maria E Lozada; Roongruedee Chaiteerakij; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.